Yee John D. 4
4 · Tempest Therapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Tempest Therapeutics (TPST) Director John D. Yee Receives 25,000-Share Award
What Happened John D. Yee, a director of Tempest Therapeutics (TPST), was granted a derivative award for 25,000 shares on June 4, 2026. The filing records the acquisition at $0 (derivative), consistent with a stock option grant rather than an open-market purchase or cash exercise. The transaction was reported on a Form 4 filed June 17, 2026.
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-17 (late).
- Transaction type: Grant / award of a derivative security (code A).
- Shares involved: 25,000 (acquired at $0 as a derivative grant).
- Vesting: Per footnote, the options vest over three years—1/3 on the first anniversary, then monthly installments thereafter, subject to continued service.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Timeliness: Filing reported late due to an “inadvertent administrative oversight” (remark in the Form 4).
Context This was a compensation grant (stock option-style award) that vests over time and is not an immediate purchase or sale. Grants are common for executives and directors and do not by themselves indicate buying or selling activity in the open market. The late filing is noted on the Form 4; while it does not change the substance of the grant, timely reporting is required by SEC rules.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-04+25,000→ 25,000 totalExercise: $1.27Exp: 2036-06-04→ Common Stock (25,000 underlying)
Footnotes (1)
- [F1]The shares subject to each such stock option will vest over a three-year period, with one-third of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.